Lee Zou

Lee Zou

Auto-generated profile, based on publicly available information

Lee Zou

Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, USA

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2013 in Cold Spring Harbor Perspectives in Biology
Verified
Journal Article
Open access
PDF file
AMAlexandre Maréchal
Alexandre Maréchal
LZLee Zou
Lee Zou
In eukaryotic cells, maintenance of genomic stability relies on the coordinated action of a network of cellular processes, including DNA replication, DNA repair, cell-cycle progression, and others. The DNA damage response (DDR) signaling pathway orchestrated by the ATM and ATR kinases is the central regulator of this network in response to DNA damage. Both ATM and ATR are activated by DNA damage and DNA replication stress, but their DNA-damage specificities are distinct and their functions are not redundant. Furthermore, ATM and ATR often work together to signal DNA damage and regulate downstream processes. Here, we will discuss the recent findings and current models of how ATM and ATR sense DNA damage, how they are activated by DNA damage, and how they function in concert to regulate the DDR.

16 June 2022 in Molecular Cell
Verified
Journal Article
Closed access
SSSneha Saxena
Sneha Saxena
LZLee Zou
Lee Zou

16 January 2015 in Science
Verified
Journal Article
Closed access
PDF file
RFRachel Litman Flynn
Rachel Litman Flynn
KCKelli E. Cox
Kelli E. Cox
MJMaya Jeitany
Maya Jeitany
Hiroaki WakimotoHiroaki Wakimoto
Hiroaki Wakimoto
ABAlysia R. Bryll
Alysia R. Bryll
LZLee Zou
Lee Zou
Cancer's alternative means to an end: To stay alive and proliferating, tumor cells must maintain their telomeres: the DNA sequences at the ends of chromosomes. The majority accomplish this by activating the enzyme telomerase. However, certain tumor types favor a different mechanism called alternative lengthening of telomeres (ALT), which involves DNA recombination. Flynn et al. delineated the molecular events that occur at the telomeres of ALT-proficient tumor cells by studying the function of a protein that is altered by mutation in these tumors. The analysis revealed a specific protein kinase that is essential for ALT, which could in principle be targeted to halt tumor growth. Science , this issue p. 273


22 April 2022 in Nature Reviews Molecular Cell Biology
Verified
Journal Article
Closed access
PDF file
EPEva Petermann
Eva Petermann
LLLi Lan
Li Lan
LZLee Zou
Lee Zou

1 February 2017 in Genes & Development
Verified
Journal Article
Open access
PDF file
SYStephanie A. Yazinski
Stephanie A. Yazinski
VCValentine Comaills
Valentine Comaills
RBRémi Buisson
Rémi Buisson
MGMarie-Michelle Genois
Marie-Michelle Genois
HNHai Dang Nguyen
Hai Dang Nguyen
LZLee Zou
Lee Zou
Poly-(ADP-ribose) polymerase (PARP) inhibitors (PARPis) selectively kill BRCA1/2-deficient cells, but their efficacy in BRCA-deficient patients is limited by drug resistance. Here, we used derived cell lines and cells from patients to investigate how to overcome PARPi resistance. We found that the functions of BRCA1 in homologous recombination (HR) and replication fork protection are sequentially bypassed during the acquisition of PARPi resistance. Despite the lack of BRCA1, PARPi-resistant cells regain RAD51 loading to DNA double-stranded breaks (DSBs) and stalled replication forks, enabling two distinct mechanisms of PARPi resistance. Compared with BRCA1-proficient cells, PARPi-resistant BRCA1-deficient cells are increasingly dependent on ATR for survival. ATR inhibitors (ATRis) disrupt BRCA1-independent RAD51 loading to DSBs and stalled forks in PARPi-resistant BRCA1-deficient cells, overcoming both resistance mechanisms. In tumor cells derived from patients, ATRis also overcome the bypass of BRCA1/2 in fork protection. Thus, ATR inhibition is a unique strategy to overcome the PARPi resistance of BRCA-deficient cancers.